Abiomed Completes Patient Enrollment In RECOVER RIGHT Impella Study

DANVERS, Mass., March 20, 2014 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced the completion of the 30th patient enrolled in RECOVER RIGHT, an Investigational Device Exemption (IDE) study of Impella® RP (Right Peripheral). The trial was designed to enroll as many as 30 patients, at 15 sites, for up to 14 days of circulatory support.

Help employers find you! Check out all the jobs and post your resume.